Rethinking CIRS: Innate Immune Dysregulation as the Upstream Driver Beyond Inflammation and Genetic Susceptibility

Author: Alli Manzella, CIRS-Literate FNTP, Environmental Health Specialist
Co-Founder, Root Cause for Crohn’s & Colitis (RCFCC)
Date: June 2025

Abstract

Chronic Inflammatory Response Syndrome (CIRS) has been defined by a specific clinical phenotype and lab profile following biotoxin exposure in genetically susceptible individuals. While the Shoemaker Protocol laid critical groundwork in establishing a reproducible diagnostic and therapeutic framework, a deeper look at a specific subgroup within the CIRS population reveals a more defined root cause. This paper proposes that innate immune dysregulation (IID) is an upstream mechanism in individuals carrying the HLA-DR4-3-53 and DR11-3-52B haplotypes, which differ mechanistically from other CIRS-susceptible types by impairing antigen presentation, promoting immune misrecognition, and failing to resolve innate inflammatory responses. These haplotypes predispose the host to chronic immune dysfunction, making them uniquely vulnerable to persistent biotoxin sensitivity and multisystem involvement. In these patients, inflammation, immune exhaustion, and persistent susceptibility to biotoxins arise from a primary loss of regulation in innate immune signaling and resolution. This insight may also help explain the immune dysfunction seen in a subset of patients with Inflammatory Bowel Disease (IBD), carrying these specific HLA haplotypes.

Introduction

CIRS is widely recognized as a multisystem, multi-symptom illness triggered by biotoxin exposure in patients carrying specific HLA-DR/DQ haplotypes. Present clinical paradigms focus on chronic innate inflammation as the defining mechanism. However, this model is insufficient. Emerging research and clinical evidence suggest that in a specific subset of genetically susceptible individuals, the true root of CIRS lies in innate immune dysfunction. This is not a universal mechanism for all with CIRS, but rather appears to be specific to those with the HLA-DR4-3-53 and DR11-3-52B haplotypes. In these individuals, the host loses the capacity to regulate recognition, clearance, and recovery processes after exposure, resulting in a state of persistent innate immune dysregulation.

1. Roles of Innate Immune Function

The innate immune system functions as the body’s first line of defense. Its roles include:

Regulation of adaptive immune responses
Pattern recognition through receptors such as TLRs, NLRs, and CLRs
Maintenance of physical and immune barriers (gut, lung, skin, brain, mucosa)
Pathogen clearance and apoptotic cell removal
Regulation of immune tolerance and inflammation resolution
Metabolic and endocrine homeostasis
Surveillance against malignancy and abnormal self-patterns

When dysregulated, this system no longer maintains homeostasis and begins to fail at its core functions:

Inadequate clearance of biotoxins and cellular debris
Breakdown of immune tolerance
Chronic misfiring of inflammatory circuits
Poor antigen presentation and signaling to adaptive immunity

Key clinical indicators of this dysfunction include:

Low α-MSH and VIP: Indicating hypothalamic and neuroimmune signaling breakdown
Low NK cell activity: Reducing innate pathogen clearance
Thymic involution: Reflecting immune aging and naïve T cell depletion
Elevated TGF-β1: A marker of compensatory immunosuppression and fibrosis

These are not merely a consequence of inflammation. They are hallmarks of failure in innate immune regulation in genetically susceptible individuals, particularly those with the DR4-3-53 and DR11-3-52B haplotypes.

2. Rethinking HLA Genetics: Marker or Mechanism?

It is true that approximately 24 percent of the population carries HLA haplotypes associated with CIRS susceptibility. However:

HLA genetics alone do not cause CIRS. They modulate risk through antigen presentation dynamics
Most individuals with “CIRS-susceptible” haplotypes remain asymptomatic until a system-stressing exposure or priming event
Genetics do not explain why the immune system fails to reset after exposure or why dysfunction persists

Two haplotypes in particular, HLA-DR4-3-53 and HLA-DR11-3-52B, are consistently linked to impaired antigen presentation, immune misrecognition, and innate immune dysfunction. These haplotypes define a distinct subset of CIRS patients in whom innate immune dysregulation is the central pathological mechanism. These same haplotypes are significant in individuals with IBD. Meta-analyses have identified HLA-DRB1*0103, DR4, and DQ4 as positively associated with Crohn’s Disease and Ulcerative Colitis, with several studies reporting odds ratios between 1.6 and 3.4. Equivalent to approximately 60 to 77 out of every 100 individuals with these haplotypes exhibiting co-occurring IBD, compared to 23 to 40 out of 100 without them. This higher prevalence strengthens the proposed mechanistic link between CIRS and the persistent inflammation and barrier breakdown seen in IBD.

Shoemaker and Heyman (2020) highlight that these genotypes create a predisposition for an overactive host response, particularly in the face of biotoxin exposure and transcriptomic immune suppression. They specifically note suppression of the CD3D gene, which is required for T cell signaling and B cell activation. This contributes to immune paralysis rather than hyperactivation and helps explain why individuals with IBD frequently show features of immune collapse rather than overt inflammation.

According to Dr. Andrew Heyman: "It is not that the immune system is weak. It is that it is stuck. We are not seeing immunosuppression in the classic sense, but transcriptomic injury that blocks immune resolution."

This level of dysregulation cannot be explained by genotype alone. It is driven by the collapse of pattern recognition, mitochondrial signaling, and immune checkpoint regulation.

Clinical implication: It is essential to focus not just on genotype, but on immune phenotype and resolution capacity post-exposure, especially in those with the DR4-3-53 and DR11-3-52B haplotypes.

3. Biotoxin Exposure: Immune Activation Trigger in Genetically Susceptible Hosts

Biotoxins like mycotoxins, endotoxins, and dinoflagellate toxins initiate immune responses via pattern recognition receptors (PRRs), such as TLR-4 and Dectin-1. However, these molecules must first penetrate physical and immune barriers to exert systemic effects.

In a healthy host:

Barriers are intact
Exposures trigger a self-limited immune response
Homeostasis is restored via resolution pathways

In a dysregulated system:

Barrier breakdown (e.g., gut, lung epithelium) facilitates systemic toxin spread
The innate immune system cannot complete its clearance cycle
Chronic cytokine signaling persists, unchecked by resolution mediators like MSH, IL-10, and Tregs

Thus, biotoxins initiate but do not sustain the CIRS phenotype. The failure of innate immune resolution is the sustaining driver in this genetically defined subset.

4. Immune Exhaustion, Metabolic Injury, and Tolerance Shifts
Shoemaker's labs often show features of immune collapse rather than classic inflammation:

Low MSH and VIP impair regulatory tone of immune and epithelial tissues
Elevated TGF-β1 and VEGF reflect compensatory anti-inflammatory shifts and tissue remodeling
T cell exhaustion and thymic involution signal an inability to replenish adaptive surveillance

Transcriptomic analysis reveals suppression of CD3D, a gene essential for antigen-presenting cell to T cell signaling. Without it, B cell activation fails, adaptive immunity collapses, and regulatory immune function is lost. This explains why so many CIRS and IBD patients present with paradoxical inflammation and immune deficiency at the same time.

Shoemaker and Heyman also describe metabolic hypometabolism in CIRS patients. Suppression of mitochondrial translocase genes prevents pyruvate from entering mitochondria, shifting energy production from oxidative phosphorylation to glycolysis. This Warburg-like metabolic pattern produces only 2 ATP per glucose instead of 36, leading to energy collapse in immune and epithelial cells.

This mirrors findings in chronic infections, cancer, and post-sepsis states, where inflammation transitions to immune exhaustion and redox collapse. In each of these conditions, unresolved immune activation leads to metabolic rewiring, loss of immune vigilance, and systemic energy failure. These patterns closely parallel the mechanisms observed in CIRS. Studies have documented similar transcriptomic and metabolic profiles across these states, supporting the comparison.

This downstream immune failure is not solely a consequence of genetic predisposition, but rather reflects a primary failure of innate immune regulation. In individuals with specific HLA haplotypes, unresolved innate immune activation leads to impaired resolution capacity, contributing to the chronic immune dysfunction that characterizes CIRS.

5. Implications for Clinical Practice
If CIRS is understood purely as a chronic inflammatory syndrome in genetically predisposed individuals, the therapeutic focus will remain limited to:

HLA typing as risk stratification
Anti-inflammatories (fish oil, bile acid sequestrants, VIP)
Sequential antimicrobial therapies or anti-biofilm agents

However, by identifying innate immune dysregulation as the upstream dysfunction in a specific genetically susceptible subset, new treatment priorities emerge:

Restoring neuroimmune peptides: Using melanocortin stimulation, photobiomodulation, vagus nerve activation
Rebuilding epithelial and mucosal barriers: Targeted supplemental therapies, peptides, immunoglobulins, mucosal repair agents
Retraining innate surveillance systems: Including immunomodulatory peptides, microbial reprogramming, and Site Specific Immunomodulators (SSI)
Monitoring immune reconstitution: Not just inflammation reduction, but restoration of NK cells, MSH/VIP, and naive T cell pools

Conclusion

CIRS is not merely a disorder of chronic inflammation driven by HLA genetic susceptibility, biotoxin exposure, and failed clearance. In a specific subset of individuals with the HLA-DR4-3-53 and DR11-3-52B haplotypes, it represents a syndrome rooted in innate immune dysregulation. The process is initially triggered by biotoxins that breach barrier function and is sustained by a failure of immune resolution. While inflammation and genetic predisposition contribute to the clinical picture, they are secondary factors in the chronicity of this condition. . By redirecting the clinical focus toward restoring innate immune function in this defined subgroup, we create the possibility for deeper recovery, regulation of adaptive immune responses, restoration of immune competence, increased resilience to environmental exposures, resolution of chronic infections, clearance of dysbiosis, and prevention of long-term disease progression.

This perspective also offers a transformative new framework for understanding Inflammatory Bowel Disease. Rather than viewing these conditions solely as lifelong autoimmune disorders, this genetically defined subset may be more accurately characterized as environmentally induced and potentially immune-resolvable syndromes, with a clear upstream mechanism and measurable markers of immune recovery.

References

Shoemaker RC, et al. Inflammation Induced by Innate Immune Response to Biotoxins. [PMCID: PMC3654245]
Zhang C, et al. Immune Dysfunction in Chronic Mold Illness: A Role for T Cell Exhaustion and NK Cell Deficiency. Frontiers in Immunology. [PMCID: PMC6907648]
Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014. [PMCID: PMC4202368]
Oja AE, et al. Triggering of the immune checkpoint CD161 in innate immune cells leads to immune suppression. Cell Reports. [PMCID: PMC7703256]
Shoemaker R, Heyman A, Lark D. COVID-19: What is Compromised in Immunocompromised? The Overactive Host Response Holds the Danger. Surviving Mold, 2020. https://www.survivingmold.com/legal-resources/dr.-shoemaker-essays/covid-19-what-is-compromised-in-immunocompromised-the-overactive-host-response-holds-the-danger